Market Cap
€16.4b
Last Updated
2020/06/06 23:35 UTC
Data Sources
Company Financials +
Executive Summary
Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide.
Snowflake Analysis
Solid track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Grifols's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GRF has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-1.6%
GRF
-1.7%
ES Biotechs
8.7%
ES Market
1 Year Return
14.0%
GRF
18.6%
ES Biotechs
-13.6%
ES Market
Return vs Industry: GRF underperformed the Spanish Biotechs industry which returned 18.6% over the past year.
Return vs Market: GRF exceeded the Spanish Market which returned -13.6% over the past year.
Shareholder returns
| GRF | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.6% | -1.7% | 8.7% |
| 30 Day | -4.9% | -6.5% | 15.6% |
| 90 Day | -4.3% | -2.1% | -5.6% |
| 1 Year | 14.6%14.0% | 19.2%18.6% | -11.0%-13.6% |
| 3 Year | 13.9%10.6% | 27.0%24.5% | -19.1%-26.6% |
| 5 Year | 62.6%54.2% | 60.2%55.1% | -9.8%-24.3% |
Price Volatility Vs. Market
How volatile is Grifols's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Is Now The Time To Put Grifols (BME:GRF) On Your Watchlist?3 weeks ago | Simply Wall St
What Kind Of Investor Owns Most Of Grifols, S.A. (BME:GRF)?1 month ago | Simply Wall St
Grifols, S.A.'s (BME:GRF) Stock Is Going Strong: Have Financials A Role To Play?Valuation
Is Grifols undervalued compared to its fair value and its price relative to the market?
27.36x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GRF (€27.66) is trading above our estimate of fair value (€15.94)
Significantly Below Fair Value: GRF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GRF is good value based on its PE Ratio (27.4x) compared to the Biotechs industry average (33.7x).
PE vs Market: GRF is poor value based on its PE Ratio (27.4x) compared to the Spanish market (16.1x).
Price to Earnings Growth Ratio
PEG Ratio: GRF is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: GRF is overvalued based on its PB Ratio (3.4x) compared to the ES Biotechs industry average (2.6x).
Next Steps
Future Growth
How is Grifols forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
13.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRF's forecast earnings growth (13.2% per year) is above the savings rate (1.3%).
Earnings vs Market: GRF's earnings (13.2% per year) are forecast to grow slower than the Spanish market (18.4% per year).
High Growth Earnings: GRF's earnings are forecast to grow, but not significantly.
Revenue vs Market: GRF's revenue (6.6% per year) is forecast to grow faster than the Spanish market (4.9% per year).
High Growth Revenue: GRF's revenue (6.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GRF's Return on Equity is forecast to be low in 3 years time (16.4%).
Next Steps
Past Performance
How has Grifols performed over the past 5 years?
5.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GRF has high quality earnings.
Growing Profit Margin: GRF's current net profit margins (13.3%) are higher than last year (12.3%).
Past Earnings Growth Analysis
Earnings Trend: GRF's earnings have grown by 5% per year over the past 5 years.
Accelerating Growth: GRF's earnings growth over the past year (22.8%) exceeds its 5-year average (5% per year).
Earnings vs Industry: GRF earnings growth over the past year (22.8%) exceeded the Biotechs industry 16.5%.
Return on Equity
High ROE: GRF's Return on Equity (10.2%) is considered low.
Next Steps
Financial Health
How is Grifols's financial position?
Financial Position Analysis
Short Term Liabilities: GRF's short term assets (€3.7B) exceed its short term liabilities (€1.3B).
Long Term Liabilities: GRF's short term assets (€3.7B) do not cover its long term liabilities (€7.4B).
Debt to Equity History and Analysis
Debt Level: GRF's debt to equity ratio (89.6%) is considered high.
Reducing Debt: GRF's debt to equity ratio has reduced from 150.8% to 89.6% over the past 5 years.
Debt Coverage: GRF's debt is not well covered by operating cash flow (13%).
Interest Coverage: GRF's interest payments on its debt are well covered by EBIT (6.9x coverage).
Balance Sheet
Next Steps
Dividend
What is Grifols's current dividend yield, its reliability and sustainability?
1.25%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GRF's dividend (1.25%) isn’t notable compared to the bottom 25% of dividend payers in the Spanish market (2.51%).
High Dividend: GRF's dividend (1.25%) is low compared to the top 25% of dividend payers in the Spanish market (6.7%).
Stability and Growth of Payments
Stable Dividend: GRF is not paying a notable dividend for the Spanish market, therefore no need to check if payments are stable.
Growing Dividend: GRF is not paying a notable dividend for the Spanish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: GRF is not paying a notable dividend for the Spanish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GRF's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
12.4yrs
Average management tenure
CEO
Raimon Grifols Roura (55yo)
3.42yrs
Tenure
Mr. Raimon Grifols Roura has been the Co-Chief Executive Officer of Grifols, S.A. since January 1, 2017 and served as its Co-Chairman. Mr. Roura was a Patner at Osborne Clarke Spain. Mr. Roura serves as th ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-CEO & Executive Director | 3.42yrs | no data | 0.00041% €67.2k | |
| Vice Secretary & External Director | 20.17yrs | no data | 0.015% €2.5m | |
| Co-CEO & Executive Director | 4.08yrs | no data | 0.0021% €350.7k | |
| CFO & VP | 13.42yrs | no data | no data | |
| Corporate Vice President and Director of Scientific & Medical Affairs | 13.42yrs | no data | no data | |
| Vice President of Corporate Treasury & Investor Relations | no data | no data | 0.0029% €468.7k | |
| General Counsel & Chief Innovation Officer | 17.42yrs | no data | 0.0029% €478.6k | |
| Vice President of Corporate Communications | 2.42yrs | no data | 0.00010% €16.4k | |
| Corporate VP & Chief Human Resources Officer | 12.42yrs | no data | 0.00014% €22.9k | |
| Corporate Vice President and President of the Biological Industrial Group | 25.42yrs | no data | no data |
12.4yrs
Average Tenure
61yo
Average Age
Experienced Management: GRF's management team is seasoned and experienced (12.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-CEO & Executive Director | 3.42yrs | no data | 0.00041% €67.2k | |
| Vice Secretary & External Director | 20.17yrs | no data | 0.015% €2.5m | |
| Co-CEO & Executive Director | 4.08yrs | no data | 0.0021% €350.7k | |
| Independent Non-Executive Vice-Chairman | 3.42yrs | €845.00k | 0.0054% €890.0k | |
| Non-Executive Chairman | 18.08yrs | €1.24m | 0.13% €21.1m | |
| Member of the Advisory Committee | 5.42yrs | €380.00k | no data | |
| Independent Other External Director | 20.17yrs | €913.00k | 0.049% €8.1m | |
| Independent Director | 6.08yrs | €125.00k | no data | |
| Lead Independent Director | 3.42yrs | €75.00k | no data | |
| Independent Director | 5.08yrs | €63.00k | 0.00022% €36.1k |
5.3yrs
Average Tenure
62yo
Average Age
Experienced Board: GRF's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Grifols, S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Grifols, S.A.
- Ticker: GRF
- Exchange: BME
- Founded: 1940
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €16.390b
- Shares outstanding: 684.14m
- Website: https://www.grifols.com
Number of Employees
Location
- Grifols, S.A.
- Avinguda de la Generalitat, 152
- Parc empresarial Can Sant Joan
- Barcelona
- Catalonia
- 8174
- Spain
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GRF | BME (Bolsas y Mercados Espanoles) | Yes | Class A Shares | ES | EUR | May 2006 |
| OZTA | DB (Deutsche Boerse AG) | Yes | Class A Shares | DE | EUR | May 2006 |
| 0RDU | LSE (London Stock Exchange) | Yes | Class A Shares | GB | EUR | May 2006 |
| GIFL.F | OTCPK (Pink Sheets LLC) | Yes | Class A Shares | US | USD | May 2006 |
| GRFE | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Class A Shares | GB | EUR | May 2006 |
| GRF | WBAG (Wiener Boerse AG) | Yes | Class A Shares | AT | EUR | May 2006 |
| OZTA | ETLX (Eurotlx) | Yes | Class A Shares | IT | EUR | May 2006 |
| GIKL.Y | OTCPK (Pink Sheets LLC) | SPONS ADR | US | USD | Jul 2009 | |
| GRFS | NasdaqGS (Nasdaq Global Select) | SP ADR REP B NVT | US | USD | Jun 2011 | |
| GRF.P | BME (Bolsas y Mercados Espanoles) | Class B Non-Voting Shares | ES | EUR | Jun 2011 | |
| 0RDV | LSE (London Stock Exchange) | Class B Non-Voting Shares | GB | EUR | Jun 2011 | |
| G0FB | DB (Deutsche Boerse AG) | SP ADR REP B NVT | DE | EUR | Jun 2011 | |
| GRFPE | BATS-CHIXE (BATS 'Chi-X Europe') | Class B Non-Voting Shares | GB | EUR | Jun 2011 | |
| GIFO.F | OTCPK (Pink Sheets LLC) | Class B Non-Voting Shares | US | USD | Jun 2011 | |
| GRFP N | BMV (Bolsa Mexicana de Valores) | Class B Non-Voting Shares | MX | MXN | Jun 2011 |
Biography
Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 23:35 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.